RGCC International

We are shifting the cancer care paradigm.

General Information
Company Name
RGCC International
Founded Year
2004
Location (Offices)
Zug, Switzerland +1
Founders / Decision Makers
Number of Employees
78
Industries
-
Funding Stage
-
Social Media

RGCC International - Company Profile

RGCC International is a pioneering company that aims to revolutionize cancer care and chronic disease treatment. Established in 2004, the company's slogan "We are shifting the cancer care paradigm" reflects its commitment. Leveraging personalized solutions, RGCC offers global accessibility to diagnostic and therapeutic options. Their innovative tests and therapies, tailored to individual needs, are showcased on rgcc-international.com. The company has not disclosed details about its industries, headquarters, or recent investments and investors.

Taxonomy: Cancer Care, Personalized Healthcare, Diagnostic Testing, Therapeutic Solutions, Global Healthcare, Research & Development, Genetics Analysis, Molecular Analysis, Clinical Research, Medical Services, Flow Cytometry, Immunology, Molecular Biology, Biochemistry

Funding Rounds & Investors of RGCC International (0)

View All

There is no investment information

Latest News of RGCC International

View All

No recent news or press coverage available for RGCC International.

Similar Companies to RGCC International

View All
RGCC International - Similar company to RGCC International
RGCC International We are shifting the cancer care paradigm.
Genomate Health - Similar company to RGCC International
Genomate Health The right drug. The first time. Every time.™ Computational-powered clinical decision support for precision oncology.
Tempus AI - Similar company to RGCC International
Tempus AI Tempus is advancing data-driven precision medicine with the practical application of AI in healthcare. It’s About Time.
BioGenex - Similar company to RGCC International
BioGenex Accelerating the pace of precision Oncology
Empire Genomics - Similar company to RGCC International
Empire Genomics The First Choice For Fluorescence In Situ Hybridization